These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

427 related items for PubMed ID: 30228865

  • 1. Recent advances in the understanding and treatment of pemphigus and pemphigoid.
    Yamagami J.
    F1000Res; 2018; 7():. PubMed ID: 30228865
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. IgG4, complement, and the mechanisms of blister formation in pemphigus and bullous pemphigoid.
    Dainichi T, Chow Z, Kabashima K.
    J Dermatol Sci; 2017 Dec; 88(3):265-270. PubMed ID: 28747266
    [Abstract] [Full Text] [Related]

  • 4. New immunomodulating drugs in autoimmune blistering diseases.
    Korman NJ.
    Dermatol Clin; 2001 Oct; 19(4):637-48, viii. PubMed ID: 11705351
    [Abstract] [Full Text] [Related]

  • 5. Coexistence of pemphigus vulgaris and bullous pemphigoid in the upper aerodigestive tract.
    Tabuchi K, Nomura M, Murashita H, Fujisawa Y, Tsuji S, Okubo H, Hara A.
    Auris Nasus Larynx; 2006 Jun; 33(2):231-3. PubMed ID: 16168587
    [Abstract] [Full Text] [Related]

  • 6. Current Clinical Trials in Pemphigus and Pemphigoid.
    Izumi K, Bieber K, Ludwig RJ.
    Front Immunol; 2019 Jun; 10():978. PubMed ID: 31130959
    [Abstract] [Full Text] [Related]

  • 7. Diagnosis and classification of pemphigus and bullous pemphigoid.
    Kershenovich R, Hodak E, Mimouni D.
    Autoimmun Rev; 2014 Jun; 13(4-5):477-81. PubMed ID: 24424192
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Treatment of bullous pemphigoid and pemphigus. The French experience, 2009 update.
    Roujeau JC, Ingen-Housz-Oro S, Leroux C, Joly P.
    G Ital Dermatol Venereol; 2009 Aug; 144(4):333-8. PubMed ID: 19755939
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Pemphigus and bullous pemphigoid.
    Nousari HC, Anhalt GJ.
    Lancet; 1999 Aug 21; 354(9179):667-72. PubMed ID: 10466686
    [Abstract] [Full Text] [Related]

  • 13. Evidence for pathogenicity of autoreactive T cells in autoimmune bullous diseases shown by animal disease models.
    Ujiie H, Shimizu H.
    Exp Dermatol; 2012 Dec 21; 21(12):901-5. PubMed ID: 23016514
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Enzyme-linked immunosorbent assay in autoimmune blistering diseases: preliminary experience of the Dermatology Department of Cagliari.
    Atzori L, Deidda S, Aste N.
    G Ital Dermatol Venereol; 2008 Feb 21; 143(1):1-8. PubMed ID: 18833046
    [Abstract] [Full Text] [Related]

  • 19. Comparison of IgG subclasses and complement binding activity of autoantibodies from patients with bullous pemphigoid and pemphigus.
    Brooks WS, Lee YY, Abell E, Deng JS.
    J Clin Lab Anal; 1989 Feb 21; 3(5):307-11. PubMed ID: 2681622
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.